Showing 3271-3280 of 5092 results for "".
- Galderma's New Face for Change Program Supports Dress for Success, Skin Cancer Foundationhttps://practicaldermatology.com/news/galdermas-new-face-for-change-program-supports-dress-for-success-skin-cancer-foundation/2460668/Galderma is launching Face for Change, a program in partnership with Dress for Success and The Skin Cancer Foundation that will allow Dysport users to give back with each treatment. Starting January 19, 2021 and ending February 28, 2021, Galderma will contribute $100
- Gene Sequencing May Quantify Risk of Skin Cancer Long Before Damage is Visiblehttps://practicaldermatology.com/news/gene-sequencing-may-quantify-risk-of-skin-cancer-long-before-damage-is-visible/2460644/New research sheds light on the carcinogenic effect of exposure to ultraviolet (UV) radiation, laying the groundwork for improvements in skin cancer risk stratification and prevention. In a study published&nbs
- LEO Pharma Taps Jörg Möller as EVP, Global Research and Developmenthttps://practicaldermatology.com/news/leo-pharma-taps-jorg-moller-as-evp-global-research-and-development/2460636/Jörg Möller is joining LEO Pharma A/S’s Global Leadership Team as Executive Vice President (EVP), Global Research and Development, effective January 1, 2021. Möller joins LEO Pharma from Bayer Pharma, where he has been EVP Head of R&D and Member of the Bayer Pha
- Colleen Goggins Joins ZO Skin Health's Board Of Directorshttps://practicaldermatology.com/news/colleen-goggins-joins-zo-skin-healths-board-of-directors-following-majority-investment-by-blackstone/2460624/Colleen Goggins is joining ZO Skin Health’s board of directors. This follows the recent acquisition of a majority stake in the business in October by funds managed by Blackstone Tactical Opportunities. As a partner and counsellor to a large variety of bu
- NRS Awards 2020 Research Grantshttps://practicaldermatology.com/news/nrs-awards-2020-research-grants/2460622/Expect to learn more about the genome of the Demodex mite, the microbiome’s role in rosacea, and the skin and eyelid lipid content of individuals with rosacea.The National Rosacea Society has awarded funding for studies—two new, plus continuing support for one ongoing study—into
- L'Oréal's SkinCeuticals Taps New GMhttps://practicaldermatology.com/news/loreals-skinceuticals-taps-new-gm/2460621/Stephanie Kramer is L'Oréal's SkinCeuticals new General Manager. Kramer was Global Senior Vice President of Marketing, Product Innovation and Retail at SkinCeuticals. Prior to joining SkinCeuticals in 2019, Kramer served as Vice President of Global Marketi
- Cutera Gives Back: Company Donates Tattoo Removal Laser to Gang Rehabilitation and Re-entry Programhttps://practicaldermatology.com/news/cutera-gives-back-company-donates-tattoo-removal-laser-to-gang-rehabilitation-and-re-entry-program/2460597/Cutera, Inc. is donating an enlighten tatoo removal laser along with clinical training and service to Homeboy Industries, a gang rehabilitation and re-entry program in Los Angeles. Homeboy Industries provides parenting classes, anger management and tattoo removal to support former
- Exclusive: Global Report Identifies Strategies for Improved Quality of Care in ADhttps://practicaldermatology.com/news/exclusive-global-report-identifies-strategies-for-improved-quality-of-care-in-ad/2460585/Gathering and synthesizing data from in-person visits from 32 care centers in 17 countries around the world, the “Improving Quality of Care in AD” report offers clear recommendations to improve care and help patients better manage atopic dermatitis.Commissioned and funded by Sano
- FDA Grants Priority Review for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe ADhttps://practicaldermatology.com/news/fda-grants-priority-review-for-pfizers-abrocitinib-an-oral-once-daily-jak1-inhibitor-for-patients-12-and-up-with-moderate-to-severe-ad/2460580/The U.S. Food and Drug Administration (FDA) has granted Priority Review designation to Pfizer’s New Drug Application (NDA) for abrocitinib (100mg and 200mg), an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor, for the treatment of moderate to severe atopic dermatitis (AD) in
- SOC, VisualDX, and NEJM Group Launch Webinar Series to Explore Issues in Skin Colorhttps://practicaldermatology.com/news/soc-visualdx-and-nejm-group-launch-webinar-series-to-explore-issues-in-skin-color/2460570/“The Impact of Skin Color and Ethnicity on Clinical Diagnosis and Research,” a new webinar series presented by the Skin of Color Society, NEJM Group, and VisualDx launches this month to call attention to health disparities and structural racism in medicine.